A Role for Biomarkers in Selecting Appropriate Patients for ADCs in NSCLC
Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.
Source: onclive.com
Page 25 - Nsclc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nsclc Today - Breaking & Trending Today
TROPION-Lung04: Dato-DXd Plus Immunotherapy in Advanced NSCLC
Joshua K. Sabari, MD, reviews data from the TROPION-Lung04 study, and the panel offers key takeaways on Dato-DXd and immunotherapy in advanced NSCLC.
Source: onclive.com
Dr Shu on Advances in Adjuvant Therapy For Early-Stage NSCLC
Catherine Ann Shu, MD, discusses key therapeutic advances in the adjuvant setting for patients with early-stage non–small cell lung cancer.
Source: onclive.com
Standard-of-Care Approaches in EGFR-Mutant NSCLC
Delve into the evolving landscape of treating EGFR mutations in lung cancer, exploring emerging therapies, structural classifications, and the complexity of individual mutation responses.
Source: onclive.com
BDTX-1535 Strives to Overcome Intrinsic and Acquired EGFR Mutations in NSCLC and GBM
Patients with non–small cell lung cancer harboring acquired EGFR mutations, such as C797S and intrinsic mutations in EGFR represent underserved populations where additional targeted therapies are needed.
Source: onclive.com